Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Statistics
Want to see HK:1276 full AI Analyst Report?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Stock Statistics & Valuation Metrics
Total Valuation
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has a market cap or net worth of HKD 371.11B. The enterprise value is HKD 281.48B.
- Market Cap
- HKD 371.11B
- Enterprise Value
- HKD 281.48B
Share Statistics
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has 258,197,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 258,197,600
- Owned by Insiders
- ―
- Owned by Institutions
- 22.14%
Financial Efficiency
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 12.55%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- 0.11
- Return on Invested Capital (ROIC)
- 12.55%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 1.71M
- Profits Per Employee
- 416.39K
- Employee Count
- 20,602
- Asset Turnover
- 0.45
- Inventory Turnover
- 1.52
Valuation Ratios
The current PE Ratio of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H is 35.61. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s PEG ratio is 2.31.
- PE Ratio
- 35.61
- PS Ratio
- 9.33
- PB Ratio
- 4.75
- Price to FCF
- 50.21
- Price to Operating Cash Flow
- 31.65
- PEG Ratio
- 2.31
Income Statement
In the last 12 months, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H had revenue of 35.19B and earned 8.58B in profits. Earnings per share was 1.32.
- Revenue
- 35.19B
- Gross Profit
- 30.33B
- Operating Income
- 10.00B
- Pretax Income
- 9.69B
- Net Income
- 8.58B
- EBITDA
- 10.63B
- Earnings Per Share (EPS)
- 1.32
Cash Flow
In the last 12 months, operating cash flow was 11.56B and capital expenditures -4.48B, giving a free cash flow of 7.08B billion.
- Operating Cash Flow
- 11.56B
- Free Cash Flow
- 7.08B
- Free Cash Flow per Share
- 0.93
Dividends & Yields
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pays an annual dividend of HKD 0.23, resulting in a dividend yield of 0.46%
- Dividend Per Share
- HKD 0.23
- Dividend Yield
- 0.46%
- Payout Ratio
- 16.52%
- Free Cash Flow Yield
- 1.99%
- Earnings Yield
- 2.80%
Stock Price Statistics
- Beta
- 0.53
- 52-Week Price Change
- -32.11%
- 50-Day Moving Average
- 47.98
- 200-Day Moving Average
- 57.46
- Relative Strength Index (RSI)
- 49.18
- Average Volume (3m)
- 5.14M
Important Dates
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H upcoming earnings date is Apr 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Apr 19, 2027
- Ex-Dividend Date
- Apr 29, 2026
Financial Position
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H as a current ratio of 8.08, with Debt / Equity ratio of 0.07%
- Current Ratio
- 8.08
- Quick Ratio
- 7.63
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -4.28
- Interest Coverage Ratio
- 626.53
Taxes
In the past 12 months, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has paid 1.10B in taxes.
- Income Tax
- 1.10B
- Effective Tax Rate
- 0.11
Enterprise Valuation
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H EV to EBITDA ratio is 26.99, with an EV/FCF ratio of 43.17.
- EV to Sales
- 8.02
- EV to EBITDA
- 26.99
- EV to Free Cash Flow
- 43.17
- EV to Operating Cash Flow
- 26.30
Balance Sheet
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has HKD 50.97B in cash and marketable securities with HKD 493.42M in debt, giving a net cash position of HKD 50.48B billion.
- Cash & Marketable Securities
- HKD 50.97B
- Total Debt
- HKD 493.42M
- Net Cash
- HKD 50.48B
- Net Cash Per Share
- HKD 195.51
- Tangible Book Value Per Share
- HKD 10.39
Margins
Gross margin is 85.93%, with operating margin of 27.43%, and net profit margin of 27.04%.
- Gross Margin
- 85.93%
- Operating Margin
- 27.43%
- Pretax Margin
- 30.52%
- Net Profit Margin
- 27.04%
- EBITDA Margin
- 29.73%
- EBIT Margin
- 28.18%
Analyst Forecast
The average price target for Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H is HKD 81.55, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- HKD 81.55
- Price Target Upside
- 65.35% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 11.35%
- EPS Growth Forecast
- 21.43%
Scores
- Smart Score
- 6
- AI Score
- 71

